Back to News
Market Impact: 0.3
AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine
Source: PR Newswire
Healthcare & Biotech
Atogepant demonstrated statistically significant reductions in migraine days associated with menstrual migraine, a recurrent and debilitating condition with predictable attacks around menstruation. The result supports the drug's clinical efficacy in a potentially underserved migraine subgroup, though the excerpt provides no numerical efficacy data, safety results, or commercial implications.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.40
More News
- Biotech stocks are surging. How investors can play the new drug innovation boom
- IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
- J&J prostate cancer drug shows promising tumor responses in early trial
- Pfizer reports phase 2 data for 25-valent pneumococcal vaccine
- Fact vs. fiction: Doctors share whether peptides are safe and effective
- Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer